ArticleMethods in molecular biology (Clifton, N.J.)2025
The Production and Characterization of Synthetic Glycoconjugate Vaccines.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- T-cell and B-cell dynamics following prime-boost immunization with W135 meningococcal conjugate vaccine in mice.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemical conjugation of polysaccharides to protein carriers has become essential in carbohydrate vaccine development to enhance the poor immunogenicity of glycans. Neutral and uncharged carbohydrates induce T-cell independent responses, failing to produce robust IgG antibodies or sustained T-cell memory and conjugating native or synthetic glycans with carrier proteins such as the Cross-Reactive-Material-197 (CRM197) diphtheria toxin mutant, tetanus toxoid, or protein D of H. influenzae eliciting T-cell-dependent immune responses and class switching that produces high-affinity antibodies. This chapter describes the most commonly used synthetic glycoconjugates preparation strategy involving a spacer and a linker carrying a functional group, mostly amine, that couples the synthetic glycan to the carrier protein through its primary amine side chains of lysine residues and N-terminus. Our detailed protocol aims to advance the development of carbohydrate-binding antibodies that target tumor-associated carbohydrate antigens and expand our toolbox in the war against cancer.
Indexed as
Identifiers
40266525What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.